Menu
Boston, MA, USA, and Lausanne, SWITZERLAND, January 19, 2021: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Kathy L. Hibbs was nominated to the company’s Board of Directors and its Audit Committee. Hibbs is an accomplished healthcare technology executive, currently holding the position of Chief Legal and Regulatory Officer at 23andMe, the leading consumer genetics and research company.
Regularly recognized as one of the Bay Area’s most influential women by both the San Francisco and Silicon Valley Business Journals, Hibbs is ranked by Chambers as among the most influential General Counsels in US. She sits on the boards of Decipher Biosciences, Inc. and Cadex Genomics Inc. During her 15 years’ experience as an executive officer and corporate secretary for two public biotechnology companies, Genomic Health, Inc. (NASDAQ: GHDX) and Monogram Biosciences, Inc. (NASDAQ: MGRM), Hibbs developed her passion for personalized medicine and the power of innovation to improve the lives of patients. She is globally recognized for her effectiveness, having successfully pioneered the first ever FDA clearance for over-the-counter genetic testing.
“We are pleased to welcome Kathy to SOPHiA’s Board of Directors,” said Jurgi Camblong, SOPHiA GENETICS’ CEO and Founder. “The company will significantly benefit from Kathy’s extensive experience in legal and regulatory affairs in the biotech industry specifically. She substantially contributed to the accessibility of genetic testing and usage of real-world evidence data, leading millions of people to more proactive health decisions, and is therefore totally aligned with our mission to democratize Data-Driven Medicine.”
“SOPHiA’s position in the market and its rapid penetration in the US make it an exciting time to join the company”, added Kathy Hibbs. “We share a common passion and a commitment to bring personalized medicine to the next chapter of its development; I find it truly inspiring, and I look forward to bringing my experience to the board.”
This latest appointment follows that of Didier Hirsch, former CFO at Agilent. Hirsch joined SOPHiA’s Board of Director in October 2020 and chairs the Audit Committee Hibbs will be a part of. These nominations take place in a wider context of professionalization of the company, to ensure consistency with the increasing regulation of an industry in constant growth.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
